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Editorial Comment
Are You Too Young?*
Deeb N. Salem, MD,†‡ Adeeb H. Al-Quthami, MD†
Boston, Massachusetts
Published by Elsevier Inc. doi:10.1016/j.jacc.2011.06.065At a time when the value of performing aortic valve
replacement surgery on elderly patients with aortic stenosis
(AS) was being questioned, we reported our findings of a
formal decision analysis entitled “You’re Never Too Old”
(1) that revealed survival benefit of surgical aortic valve
replacement (SAVR) in symptomatic elderly AS patients.
SAVR is currently widely accepted as a treatment of
otherwise healthy patients in the upper decades of life who
are suffering from severe symptomatic AS. In such patients
SAVR improves survival, symptoms, and quality of life
associated with this disease (2). With an increasingly aging
population, aortic valve replacement is now the most common
reason for valve replacement in Europe and North America.
However, approximately one-third of otherwise eligible pa-
tients for SAVR do not undergo this procedure, due to
increased surgical risk with advanced age and baseline comor-
bidities (3,4).
See page 2151
To address this unmet need for a less-invasive solution,
transcatheter aortic valve implantation (TAVI) was pio-
neered in the last decade as a treatment alternative for
inoperable or high-risk patients with severe AS. Since it was
first performed in 2002 (5), several international registries
have consistently demonstrated that TAVI is feasible and
provides at least favorable short- and medium-term proce-
dural, clinical, and hemodynamic results (6–10).
Comparative data between standard medical therapy
(MT), TAVI, and SAVR has so far been limited. Previously
nonrandomized registry data have shown comparable results
between TAVI and SAVR at 1, 6, and 12 months (11–13).
Recently, results from the randomized PARTNER Cohort A
(Placement of Aortic Transcatheter Valves) trial showed
that TAVI was noninferior to SAVR in terms of 1-year
mortality in a high-risk group of patients with severe
symptomatic AS (14). These very encouraging results from
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SAVR are difficult to extrapolate when applied to what is
encountered in a real-world group of patients that are not
selected according to strict protocol-mandated criteria. In
addition, comparative mortality and clinical results between
the different treatment strategies available beyond 1 year has
so far been very limited.
For these reasons, the prospective single-center registry
study reported by Wenaweser et al. (15) in this issue of the
Journal is of significant importance, because it provides
short-, medium-, and long-term clinical outcomes of stan-
dard MT, SAVR, and TAVI with 1 of the 2 European
commercially available percutaneous aortic valves. Although
self-reported and descriptive, this study provides important
comparative results on major clinical endpoints in 452
consecutive and unselected, mostly octogenarian patients
with symptomatic severe AS and multiple high-risk comor-
bidities for surgery followed up to 30 months. At 30 days
and 12 months, both SAVR and TAVI similarly improved
survival dramatically compared with standard MT alone.
More importantly, this study demonstrated that the large
mortality benefit for TAVI persisted beyond 12 months with
an all-cause mortality at 30 months which was lower for both
TAVI (22.6%) and SAVR (22.4%), compared with standard
MT alone (61.5%, p  0.001). Furthermore, not only did
TAVI and SAVR improve survival, but symptoms were
improved as well, with more than 90% of patients undergoing
either intervention reporting New York Heart Association
functional class I or II symptoms at 1 year, compared with only
70.8% of patients treated medically (p  0.003).
These striking results highlight several important points.
First, they reaffirmed that standard MT in patients with severe
symptomatic AS is associated with poor long-term survival
(16). Second, these findings demonstrated that, in an unse-
lected high-risk population with severe symptomatic AS,
TAVI or SAVR had resulted in similar rates of survival up to
30 months. Third, in agreement with recently published series
(7,8), the majority of patients after TAVI have significant
symptom improvement at 1 year, which suggests that not only
is survival improved but quality of life as well. Finally, this
report showed that older age and comorbidities were the main
predictors of late mortality, which implies that if TAVI use is
expanded to a younger and healthier population the outcomes
will also be expected to be very good.
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population we need to address the 2 main reservations with
the procedure. One major concern with previous TAVI
experience is an associated stroke rate that has ranged from
0.6% at 30 days (7) to 13.5% at 2 years (10). More
worrisome is the finding that approximately two-thirds of
patients who undergo TAVI will develop new and primarily
clinically silent cerebral lesions detected by diffusion-
weighted magnetic resonance imaging (17). In the study by
Wenaweser et al. (15), major stroke occurred with similar
frequency in all 3 groups at 30 months, which seems to
suggest that long-term major stroke is probably related to
the multiple comorbidities that are usually associated with
advanced age. Therefore, it is difficult to predict the rate of
clinical and the effect of subclinical strokes if TAVI is used
in a younger population.
Post-procedural aortic paravalvular regurgitation with
TAVI is relatively common, is usually trivial or mild in
nature with little clinical effect, and seems to remain stable
over time (6–8,10,14,16). Moderate and severe aortic valve
regurgitation after TAVI has been shown to correlate with
mortality and is usually due to technical difficulties (9,18).
In this report by Wenaweser et al. (15), despite 28.3% of
patients undergoing TAVI developing moderate or severe
aortic regurgitation, the overall long-term mortality and
major adverse cerebro-cardiovascular event rates with TAVI
remained excellent. Further research on the role of moderate
and severe aortic insufficiency after TAVI is paramount
before recommending its expanded use in patients with
longer life expectancies.
If and when it is approved by the U.S. Food and Drug
Administration, TAVI is expected to emerge as a valuable
treatment option in inoperable patients with symptomatic
severe AS and become an acceptable alternative to SAVR in
a select group of patients with high surgical risk. Nonethe-
less, we need to be very careful before recommending TAVI
use in younger patients for 2 reasons. First, peri-procedural
complications, especially major stroke and severe conduc-
tion abnormalities, need to be further reduced. Such com-
plications can possibly be reduced with additional expertise,
refinement of the procedure, and improvement of the
delivery systems. Second, long-term percutaneous valve
durability similar to SAVR needs to be demonstrated before
it can be recommended in patients with longer life expec-
tancies. In conclusion, large randomized clinical trials are
needed to address these concerns with TAVI, but until
then. . .“you are too young for TAVI.”
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